Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Featured trial
ACE-CL-007: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

ACE-CL-007: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

  • 1116 views
  • 25 Mar, 2021
  • 3 locations
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic

  • 215 views
  • 17 Mar, 2022
  • 41 locations
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)

The main objective of this trial is to explore the activity of chlorambucil, an alkylating agent commonly used in chronic lymphocytic leukemia treatment, in metastatic patients, gBRCA, including

  • 0 views
  • 26 Jan, 2021
  • 1 location
Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

Many trials that patients with advanced or recurrent indolent lymphoma managed with very low-dose (4Gy) limited-field RT (LD-IFRT) have shown that high response rates and durable remission can be achieved. However, the results of two phase III trials have failed to demonstrate the lasting response rate (RR) with LD-IFRT versus …

  • 7 views
  • 21 Jan, 2021
  • 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …

mycophenolate
azathioprine
monoclonal antibodies
cyclosporine
prednisone
  • 124 views
  • 18 Feb, 2022
  • 18 locations
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic

rituximab
chlorambucil
chronic lymphocytic leukemia
  • 1 views
  • 09 Apr, 2022
  • 24 locations
A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

This study is prospective, open-label, single arm observational study to assess efficacy of obinutuzumab plus chlorambucil (GC) chemotherapy in treatment nave CLL, and prognostic impact of

chlorambucil
chronic lymphocytic leukemia
fatigue
obinutuzumab
constitutional symptoms
  • 3 views
  • 15 Feb, 2022
  • 1 location
Obinutuzumab in Marginal Zone Lymphoma

significantly inferior compared to Rituximab/chlorambucil in a large randomized prospective clinical trial in treatment nave MZL with a CR rate of 56 % vs. 80%, respectively (P<0.001).Thus, it is the major

splenic marginal zone lymphoma
tositumomab
large b-cell lymphoma
remission
b-cell lymphoma
  • 25 views
  • 08 Feb, 2022
  • 14 locations
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

inferior compared to Rituximab/chlorambucil in a large randomized prospective clinical trial in treatment naïve MZL with a CR rate of 55.8% vs. 78.8%, respectively (P < 0.001). Thus, it is the major aim

  • 0 views
  • 12 Mar, 2022
  • 6 locations
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

significantly inferior compared to Rituximab/chlorambucil in a large randomized prospective clinical trial in treatment naïve MZL with a CR rate of 56 % vs. 80%, respectively (P<0.001). Thus, it is the major

rituximab
splenic marginal zone lymphoma
chlorambucil
interferon
tositumomab
  • 10 views
  • 21 Apr, 2022
  • 10 locations